AU2002222239A1 - Vaccine for treating nicotine addiction - Google Patents

Vaccine for treating nicotine addiction

Info

Publication number
AU2002222239A1
AU2002222239A1 AU2002222239A AU2223902A AU2002222239A1 AU 2002222239 A1 AU2002222239 A1 AU 2002222239A1 AU 2002222239 A AU2002222239 A AU 2002222239A AU 2223902 A AU2223902 A AU 2223902A AU 2002222239 A1 AU2002222239 A1 AU 2002222239A1
Authority
AU
Australia
Prior art keywords
vaccine
nicotine addiction
treating nicotine
nicotine
immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002222239A
Other languages
English (en)
Inventor
Timothy James Grattan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2002222239A1 publication Critical patent/AU2002222239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002222239A 2000-12-20 2001-12-14 Vaccine for treating nicotine addiction Abandoned AU2002222239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0031079.7 2000-12-20
GBGB0031079.7A GB0031079D0 (en) 2000-12-20 2000-12-20 Vaccine
PCT/GB2001/005570 WO2002049667A2 (en) 2000-12-20 2001-12-14 Vaccine for treating nicotine addiction

Publications (1)

Publication Number Publication Date
AU2002222239A1 true AU2002222239A1 (en) 2002-07-01

Family

ID=9905473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002222239A Abandoned AU2002222239A1 (en) 2000-12-20 2001-12-14 Vaccine for treating nicotine addiction

Country Status (9)

Country Link
US (1) US20050100901A1 (ja)
EP (1) EP1343526B1 (ja)
JP (1) JP2004517846A (ja)
AT (1) ATE330627T1 (ja)
AU (1) AU2002222239A1 (ja)
DE (1) DE60121035T2 (ja)
ES (1) ES2266097T3 (ja)
GB (1) GB0031079D0 (ja)
WO (1) WO2002049667A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
RU2477753C2 (ru) * 2008-12-09 2013-03-20 Коули Фармасьютикал Груп, Инк. Иммуностимулирующие олигонуклеотиды
TWI455722B (zh) * 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
KR101648960B1 (ko) * 2011-04-15 2016-08-22 서울대학교산학협력단 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164504A (en) * 1991-01-16 1992-11-17 Abbott Laboratories Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6455047B1 (en) * 1997-09-19 2002-09-24 Serex, Inc. Methods to improve immunogenicity of antigens and specificity of antibodies
SE9801923D0 (sv) * 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal

Also Published As

Publication number Publication date
EP1343526B1 (en) 2006-06-21
GB0031079D0 (en) 2001-01-31
ES2266097T3 (es) 2007-03-01
US20050100901A1 (en) 2005-05-12
ATE330627T1 (de) 2006-07-15
EP1343526A2 (en) 2003-09-17
JP2004517846A (ja) 2004-06-17
DE60121035T2 (de) 2006-11-16
WO2002049667A2 (en) 2002-06-27
DE60121035D1 (de) 2006-08-03
WO2002049667A3 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
AU2001259639A1 (en) Device, system and method for preventing collapse of the upper airway
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
MXPA02011427A (es) Procedimiento para revestir dispositivos medicos utilizando dioxido de carbono supercritico.
EP1421804A4 (en) VIRTUAL LINK USING A WIRELESS DEVICE
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
AU2001296217A1 (en) Magnetically navigated pacing leads, and methods for delivering medical devices
GB9817052D0 (en) Vaccine
ZA200205386B (en) Systems and methods for reducing intraocular pressure.
MXPA02012819A (es) Dispositivo y metodo para tratamiento intravaginal o transvaginal de infecciones fungales, bacterianas, virales o parasitarias.
AU2003245190A1 (en) Spacer preferably made entirely of ceramic and with an adapter
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
WO2003039470A3 (en) Polyvalent immunogen of hiv
HK1068502A1 (en) Passive immunisation against bacillus anthracis.
MXPA02009275A (es) Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
AU2001250892A1 (en) Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n-(4-methoxyphenyl)-3-chloropropionamide
EP1467771A4 (en) MYCOBACTERIAL VACCINE
IL154776A0 (en) Method for the preparation of 21-hydroxy-6, 19-oxidoprogesterone and derivatives thereof
AU2002222239A1 (en) Vaccine for treating nicotine addiction
WO2004091524A3 (en) Respiratory virus vaccines
AU1865500A (en) Stabile and sterile emulsion which contains taxanes, and method for the production thereof
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
NL194910B (nl) Verzwakte stam van Pseudomonas aeruginosa, alsmede een vaccin en een geneesmiddel tegen Pseudomonas aeruginosa-infecties, en een werkwijze ter bereiding van het vaccin.
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
WO2002024223A3 (en) Prevention and treatment of streptococcal and staphylococcal infection